Century Therapeutics, Inc. (IPSC) Debt Components
- 2026-06-30: Debt Instrument, Increase (Decrease), NetUSD 6 month · $1.48M; Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
- 2026-03-31: Debt Instrument, Increase (Decrease), NetUSD 3 month · $1.37M; Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
- 2025-12-31: Debt Instrument, Increase (Decrease), NetUSD 12 month · $393.00K; Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
- 2024-12-31: Debt Instrument, Increase (Decrease), NetUSD 12 month · $1.25M; Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
Century Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt Instrument, Increase (Decrease), Net USD | Long-term Debt and Lease Obligation, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium), Net USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 6 month · $1.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | 3 month · $1.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | 12 month · $393.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | 12 month · $1.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | 12 month · $1.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | 6 month · $1.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | 3 month · $855.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $10.30M | (m) | $10.39M | $10.39M | (m) | (m) | (m) | $10.00M | $8.00K |
| 2022-12-31 | (m) | $6.50M | $3.74M | (m) | (m) | (m) | (m) | (m) | $10.00M | $8.00K |
| 2022-12-31 | 12 month · $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $10.39M | $6.50M | $3.89M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.04M | $6.14M | $10.39M | $6.54M | $3.85M | (m) | (m) | $10.00M | $12.00K |
| 2022-06-30 | (m) | $1.59M | $8.50M | $10.39M | $6.54M | $3.85M | (m) | (m) | $10.00M | $16.00K |
| 2022-03-31 | (m) | (m) | $10.02M | $10.39M | $6.55M | $3.85M | (m) | (m) | $10.00M | $21.00K |
| 2021-12-31 | 12 month · $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.04M | $8.90M | (m) | (m) | (m) | (m) | (m) | $10.00M | $25.00K |
| 2021-12-31 | (m) | (m) | (m) | $10.39M | $1.04M | $6.60M | $2.75M | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $10.39M | (m) | $1.04M | $6.60M | $2.75M | $10.00M | $29.00K |
| 2021-06-30 | (m) | (m) | (m) | $10.39M | (m) | $1.04M | $6.60M | $2.75M | $10.00M | $33.00K |
| 2020-12-31 | (m) | (m) | $9.64M | (m) | (m) | (m) | (m) | (m) | $10.00M | $43.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |